Development of a formulation that enhances gene expression and efficacy following intraperitoneal administration in rabbits and mice
Open Access
- 1 April 2003
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 7 (4) , 558-564
- https://doi.org/10.1016/s1525-0016(03)00057-1
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerCancer Gene Therapy, 2002
- Transcriptional Targeting for Ovarian Cancer Gene TherapyGynecologic Oncology, 2001
- Cationic Liposome-MediatedE1AGene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical TrialJournal of Clinical Oncology, 2001
- Selective Expression of Nonsecreted Interferon by an Adenoviral Vector Confers Antiproliferative and Antiviral Properties and Causes Reduction of Tumor Growth in Nude MiceJournal of Interferon & Cytokine Research, 2001
- Adenoviral-Mediated Suicide Gene Therapy for Ovarian CancerMolecular Therapy, 2000
- Genetic Targeting of Adenoviral VectorsMolecular Therapy, 2000
- Reduction of the viral load of HIV-1 after the intraperitoneal administration of dextrin 2-sulphate in patients with AIDSAIDS, 1998
- Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface ExposureJNCI Journal of the National Cancer Institute, 1997
- Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solutionBritish Journal of Cancer, 1996
- Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinomaBritish Journal of Cancer, 1994